Dr. Elena Panagiotopoulou, interim Director of the Ministry of Health’s Pharmaceutical Services, told that further Covid vaccines and medications against SARS-CoV-2, as well as other novel COVID-19 therapies, are only a matter of time.
She also stated that Cyprus engages indirect procurement procedures and would be able to obtain them as soon as they are authorized.
According to Panagiotopoulou, there is a lot of movement in vaccines and other treatment techniques, and “we’re getting close to licensing and availability.”
She said that the Valneva vaccine, which is an inactivated whole-virus vaccine rather than mRNA or the adenovirus vaccine, will be approved in December. The Sinopharm and Sinovac firms in China employ similar technologies in their vaccines.
She also stated that the examination of the antiviral tablet, molnupiravir or MSD, would begin at the end of the month, and that this medication is likely to have an impact.
Dr. Papagiotopoulou stated that the European Medicines Agency (EMA) has begun an investigation into the application to expand the use of BioNTech/COVID-19 Pfizer’s vaccine, Comirnaty, to children aged 5 to 11 years, and that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has begun a rolling review of Evusheld (also known as AZD7442) Long-Acting Antibody Cocktail, which is a combination of
She also stated that the EMA’s rolling examination of CureVac AG’s COVID-19 vaccine had come to an end after the business notified the Agency that it would be withdrawing from the process.
In addition, she stated that the European Medicines Agency (EMA) has begun testing Ronapreve in the treatment of COVID-19. Regeneron Pharmaceuticals Inc. and Roche Registration GmbH created Ronapreve, which is a mixture of two synthetic anti-Spike monoclonal antibodies (Casirivimab and Imdevimab).
COVID-19 inpatients who do not require supplemental oxygen therapy but are at risk of getting very sick will benefit from this treatment. It’s also for COVID-1 prevention in adults and children aged 12 and up.
Dr. Panagiotopoulou also stated that mixing and matching vaccinations had no negative consequences.
She informed CNA that the third COVID-19 vaccine, Pfizer or Moderna, is exclusively done using mRNA vaccines.
According to her, no major negative effects from immunisation with a different business or technology vaccine than the original have been reported in Cyprus.
She claimed there was just one adverse response from the third dosage, and it wasn’t from the mix and match, but from Pfizer. She went on to say that the adverse effect was minimal and tolerable.
Cyprus, she noted, adheres to European standards and EMA data, and is part of the EMA’s data pool.
According to the Ministry of Health’s Pharmaceutical Services website, 601,051 persons on the island got the first dosage and 566,481 had finished the two-dose regimen as of October 19.
A total of 32,066 people received the booster injection.